Sponsored by
Exciting report. This combination of the drugs drugs atezolizumab and ipatasertib were tried on 10 glioblastoma patients. They report two patients did very well, and these patients had a PTEN mutation. Atezolizumab is a PDL1 inhibitor, and is easily available. Ipatasertib is an experimental small molecule inhibitor of AKT and hard to get. I would like to see this tried in a larger trial.